"Today marks another milestone for COVAX", said Dr. Seth Berkley, chief executive officer (CEO) of Gavi, the Vaccine Alliance, which leads COVAX procurement and delivery.
Tedros added: "It is not vaccines on their own that will help end the pandemic, it is vaccination". -BioNTech SE vaccine or four weeks for the Moderna Inc. shot.
Both doses of the vaccine require patients to return for a booster.
While patients should receive their second shot from the same producer, the CDC has said that the second dose of either companies' vaccine could see delays of up to 6 weeks if necessary. Anaphylaxis to vaccines is uncommon but well-established - with flu shots, for instance, it occurs about 1.3 times per million doses administered, according to CDC officials.
Ten people - all women - experienced the potentially deadly allergic reaction after receiving their first dose of the shot, with nine cases reported within 15 minutes of vaccination.
For these reasons, the CDC is recommending that all vaccine sites have doses of epinephrine on hand, and that people who get vaccinated should wait 30 minutes at the vaccine site before heading off, just in case something happens.
The numbers represent 2.5 cases of anaphylactic shock per one million Moderna injections, compared with 11.1 cases per one million Pfizer injections, according to the CDC study.
"We will provide the vaccine to Covax for these countries at a not-for-profit basis".
Both vaccines authorized for emergency use in the USA were cleared based on trials that used two doses weeks apart.
Set up last year, Covax initially aimed to secure enough Covid-19 vaccines this year for the most vulnerable 20% in participating countries. All 200 million doses are expected to be delivered by July 31, 2021, allowing for 100 million people to be vaccinated.
Gavi chief executive Seth Berkley said almost 150 million doses of the AstraZeneca-Oxford vaccine were ready to ship through Covax, pending emergency use approval from the World Health Organization, which is on course to happen in mid-February.
The report says 1,266 adverse events, or 0.03 percent of the total doses administered, were reported. Covax still needs to finalise a supply agreement for the Pfizer-BioNTech vaccine.